Table 2.
Findings from the thematic analysis on the final data excerpted from the included studies
| Theme | Subtheme | Reference |
|---|---|---|
| Accessibility, Convenience and Adaptability | Accessibility to low–resource settings and vulnerable groups | (Seppälä et al., 2019; Ashfaq et al., 2020; Cliffe et al., 2021; Kruse et al., 2022; Zhou et al., 2022) |
| Increased access to evidence–based care | (Feldman et al., 2021) | |
| Convenience | (Cliffe et al., 2021) | |
| Adaptability | (Berrouiguet et al., 2016) | |
| Patient–centeredness | Encouraging treatment in resistant populations | (Berrouiguet et al., 2016) |
| Positive user experience | (Cliffe et al., 2021) | |
| Interactivity | (Berrouiguet et al., 2016; Feldman et al., 2021) | |
| Adherence | (Naslund et al., 2015) | |
| Patient empowerment | (Feldman et al., 2021) | |
| Personalization | (Naslund et al., 2015; Sakamoto et al., 2022; Zhou et al., 2022) | |
| Timeliness | (Seppälä et al., 2019) | |
| Data insights | Real–time data | (Feldman et al., 2021) |
| Objective data | (Seppälä et al., 2019) | |
| Long–term data | (Seppälä et al., 2019) | |
| Efficiency and Effectiveness | Cost–saving | (Naslund et al., 2015; Kruse et al., 2022) |
| Treatment outcomes | (Naslund et al., 2015; Gire et al., 2017; Ashfaq et al., 2020; Dosani et al., 2020; Cliffe et al., 2021; Feldman et al., 2021; Kruse et al., 2022; Sakamoto et al., 2022; Zhou et al., 2022) |